Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib +/- Bortezomib and Dexamethasone in Relapsed/Refractory AL Amyloidosis
NCT03130348Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Mar 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ibrutinib in immunoglobulin light chain amyloidosis, sponsored by Mayo Clinic. Planned start Mar 2018; status: withdrawn.
02
Drugs
ibrutinib
03
Conditions
immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT03130348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130348.